TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00

TScan Therapeutics (NASDAQ:TCRX) had its price target hoisted by Wedbush from $4.00 to $5.00 in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other research firms have also issued reports on TCRX. Morgan Stanley lowered shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. HC Wainwright dropped their price objective on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.00.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $1.12 on Thursday. TScan Therapeutics has a 12 month low of $0.88 and a 12 month high of $2.57. The company has a quick ratio of 6.44, a current ratio of 8.41 and a debt-to-equity ratio of 0.26. The stock has a market cap of $63.56 million, a PE ratio of -1.12 and a beta of 1.03. The business has a fifty day simple moving average of $1.06 and a 200-day simple moving average of $1.39.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.09. TScan Therapeutics had a negative return on equity of 79.36% and a negative net margin of 1,256.81%.The firm had revenue of $2.57 million for the quarter. On average, sell-side analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 80,069 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were purchased at an average price of $0.90 per share, with a total value of $72,062.10. Following the completion of the transaction, the insider owned 7,937,416 shares in the company, valued at $7,143,674.40. The trade was a 1.02% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have purchased a total of 161,801 shares of company stock worth $145,621 over the last 90 days. 4.35% of the stock is currently owned by company insiders.

Institutional Trading of TScan Therapeutics

Several large investors have recently added to or reduced their stakes in TCRX. Panagora Asset Management Inc. acquired a new position in shares of TScan Therapeutics during the 4th quarter worth $25,000. HRT Financial LP acquired a new position in TScan Therapeutics during the fourth quarter worth $26,000. Catalyst Funds Management Pty Ltd bought a new position in TScan Therapeutics during the second quarter valued at about $26,000. Quadrature Capital Ltd acquired a new stake in shares of TScan Therapeutics in the second quarter worth about $33,000. Finally, Boothbay Fund Management LLC lifted its position in shares of TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after buying an additional 8,121 shares during the last quarter. 82.83% of the stock is owned by institutional investors.

Key Stories Impacting TScan Therapeutics

Here are the key news stories impacting TScan Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple 2026–2028 EPS forecasts (Q1–Q4 2026 and FY2026–FY2028), lifting FY2026 from ($0.88) to ($0.76) and improving several quarterly loss estimates — and reiterating a “Buy” rating with a $7 price target. The firm’s view reduces near‑term downside in estimates and provides a sizable upside reference point for investors. HC Wainwright research note
• Positive Sentiment: Wedbush raised its price target from $4.00 to $5.00 and maintained an Outperform rating — another independent price‑target lift that can attract investor interest given the stock’s current low base. Benzinga article
• Neutral Sentiment: HC Wainwright also published a FY2030 projection (EPS ≈ ($0.09)), extending visibility far into the future; long‑range estimates are informative but carry high uncertainty for a pre‑commercial/clinical‑stage biotech. HC Wainwright long‑term model
• Negative Sentiment: HC Wainwright slightly lowered its FY2029 EPS forecast (to ($0.49) from ($0.47)), a modest downgrade that highlights ongoing long‑term uncertainty; the company remains unprofitable and consensus EPS is still negative (≈ ($1.12) current full‑year estimate), keeping valuation tied to clinical progress and execution risk. HC Wainwright note

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.